Q BioMed (OTCQB:QBIO) announced today that it signed an agreement for its Strontium89 drug to be included on the Federal Supply Schedule (FSS). New York-based Q BioMed’s agreement with the U.S. government provides U.S. veterans and other federal government agencies and eligible patients access to Strontium89, a treatment for metastatic bone pain related to common […]
qbiomed
Q Biomed seeks FDA nod for new manufacturing facility
Q Biomed (OTC:QBIO) and Bio-Nucleonics, the company licensing Q Biomed’s strontium chloride injection, have asked the FDA to approval a new manufacturing facility for the drug. Strontium-89 is a non-opioid injectable designed to relieve pain in patients with metastatic bone disease. The drug is given in a single injection and takes two weeks to reach its […]
Q Biomed looks to dust off shelved cancer pain drug
Denis Corin has spent the last 13 years in the biopharmaceutical industry watching and learning from scientists and companies that fail. “I’ve seen so many promising and innovative young technologies really struggle along or die on the vine because they’re run by scientists who don’t really understanding capital raising,” he told Drug Delivery Business News. “They run […]